Search

Your search keyword '"Langsenlehner, Uwe"' showing total 215 results
Start Over Author "Langsenlehner, Uwe"
215 results on '"Langsenlehner, Uwe"'

7. Somatische Veränderungen im Alter

Author

Langsenlehner, Uwe, Muchar, Heike, Schippinger, Walter, Pinter, Georg, editor, Likar, Rudolf, editor, Schippinger, Walter, editor, Janig, Herbert, editor, Kada, Olivia, editor, and Cernic, Karl, editor

Published
2013
Full Text
View/download PDF

8. The Functional Erythropoetin rs1617640 Gene Polymorphism does not Affect Life Expectancy of Patients with Peripheral Arterial Disease.

Author

Renner, Wilfried, Langsenlehner, Uwe, and Langsenlehner, Tanja

Abstract

Background: A common functional variant (c.-1306A>C, rs1617640) in the gene encoding erythropoietin (EPO) has been linked to expression of erythropoietin and markers of erythropoiesis. Aim of the current study was the analysis of the role of this polymorphism for long term survival of patients with peripheral arterial disease (PAD). Methods: EPO genotypes as well as biomarkers for erythropoiesis were analyzed in a cohort of 946 patients with PAD. Survival follow-up was performed 20 years af-ter recruitment of patients. Results: Twenty years after recruitment, 752 (79.5%) patients were dead, 103 (10.9%) were still alive, and 91 (9.6%) were lost-to-follow up. In a Cox regression analysis including smoking habit, sex, type-2 diabetes, hypercholesterolemia and arterial hypertension, EPO genotypes were not associated with overall survival (Hazard ratio 0.63; 95% confidence interval 0.88-1.08, p = 0.63). Conclusions: The functional EPO rs1617640 gene polymorphism, irrespective of its association with markers of erythropoiesis, does not affect survival of PAD patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. BCL2-Genotypen und Überleben bei Prostatakrebs.

Author

Renner, Wilfried, Langsenlehner, Uwe, Krenn-Pilko, Sabine, Eder, Petra, and Langsenlehner, Tanja

Subjects
ANTIANDROGENS, PROSTATE tumors treatment, ALLELES, COMBINED modality therapy, GENETIC polymorphisms, LONGITUDINAL method, COMPUTERS in medicine, PROSTATE tumors, PROTEINS, PSYCHOLOGICAL tests, RADIATION doses, RADIOTHERAPY, SURVIVAL analysis (Biometry), TUMOR classification, PROPORTIONAL hazards models, KAPLAN-Meier estimator, GENOTYPES, TUMOR grading, DYADIC Adjustment Scale, THERAPEUTICS
Abstract

Copyright of Strahlentherapie und Onkologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2017
Full Text
View/download PDF

46. The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients.

Author

Krenn-Pilko, Sabine, Langsenlehner, Uwe, Stojakovic, Tatjana, Pichler, Martin, Gerger, Armin, Kapp, Karin, and Langsenlehner, Tanja

Abstract

Existing preclinical and clinical data suggest that the presence of a systemic inflammatory response plays a critical role in the progression of several solid tumors. The derived neutrophil-to-lymphocyte ratio (dNLR) represents an easily determinable marker of systemic inflammation and has been proposed as a potential prognostic marker. The present study was performed to validate and further clarify the prognostic relevance of an elevated pre-treatment dNLR in a large cohort of European breast cancer patients. Data from 762 consecutive female breast cancer patients treated from 1999 to 2004 were evaluated. Disease-free survival (DFS) and overall survival (OS) were assessed using the Kaplan-Meier method. To evaluate the prognostic relevance, univariate and multivariate Cox regression models were performed for each endpoint. Applying receiver operating characteristics (ROC) analysis, the optimal cutoff level for the dNLR was 3. In univariate analysis, a dNLR ≥3 was associated with poor DFS (hazard ratio (HR) 1.87, 95 % confidence interval (CI) 1.28-2.73, p = 0.001) and OS (HR 1.67, 95 % CI 1.07-2.63, p = 0.025). Multivariate analysis revealed a significant association between the elevated dNLR and poor DFS (hazard ratio (HR) 1.70, 95 % CI 1.09-2.65, p = 0.018) but did not show a significant association between the dNLR and OS (HR 1.54, 95 % CI 0.91-2.59, p = 0.106). The present study shows that the pre-treatment dNLR is an independent prognostic factor that could be useful for future individual risk assessment in breast cancer patients. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results